Jubilant Pharmova Secures Shareholder Approval for Debt Securities Fundraising

New Delhi, November 21, 2026: Jubilant Pharmova Limited has received shareholder approval for issuing non-convertible debentures (NCDs) through private placement, clearing an important corporate authorisation requirement for the pharmaceutical company's debt fundraising programme.

The special resolution was approved through a postal ballot concluded on November 20, 2026, with approximately 99.39% of the votes cast supporting the proposal.

The approval permits the company to issue non-convertible debt securities through private placement, subject to an aggregate outstanding limit of ₹2,500 crore at any point during the one-year authorisation period.

The development follows Jubilant Pharmova's October 12 board approval for an NCD issue of up to ₹800 crore.

The company subsequently completed the allotment of ₹800 crore of unsecured, rated, listed and redeemable NCDs on November 5, carrying an annual coupon of 8.50% and a tenure of three years.

The latest shareholder approval provides broader flexibility for debt issuance beyond the earlier specific transaction, subject to the authorised outstanding limit and applicable regulations.

Importantly, the ₹2,500 crore approval represents a borrowing authorisation ceiling rather than confirmation that the company has raised an additional ₹2,500 crore.

Key Details of Jubilant Pharmova's NCD Approval

Parameter

Details

Company

Jubilant Pharmova Limited

Shareholder approval date

November 20, 2026

Approval mechanism

Postal ballot through remote e-voting

Resolution type

Special resolution

Proposed instrument

Non-convertible debt securities

Fundraising method

Private placement

Maximum outstanding authorisation

₹2,500 crore

Authorisation period

One year

Votes in favour

12,58,87,158

Votes against

7,73,157

Approval percentage

99.3895%

Earlier NCD allotment

₹800 crore

Earlier NCD allotment date

November 5, 2026

Coupon on allotted NCDs

8.50% annually

Tenure of allotted NCDs

Three years

NSE symbol

JUBLPHARMA

BSE equity code

530019

BSE debt code

978381

Postal Ballot Resolution Receives 99.39% Shareholder Support

The company disclosed the voting results and scrutiniser's report to the stock exchanges on November 20.

The resolution received 12,58,87,158 votes in favour and 7,73,157 votes against.

A total of 12,66,60,315 votes were cast, representing approximately 79.52% of the company's outstanding equity shares.

Shareholder voting outcome — November 20, 2026

99.39%

Resolution approved

 
 

In favour: 99.3895%

Against: 0.6104%

The strong majority satisfied the voting requirement for passing the special resolution.

The resolution is deemed to have been passed on November 20, the final date specified for remote e-voting.

The company had previously circulated the postal ballot notice on October 21, 2026.

Institutional and Retail Shareholders Back the Proposal

The voting results show substantial support across shareholder categories.

Shareholder Category

Votes in Favour

Votes Against

Approval

Promoter and promoter group

7,59,38,622

0

100%

Public institutions

3,96,53,808

7,72,247

98.09%

Public non-institutions

1,02,94,728

910

99.99%

Total

12,58,87,158

7,73,157

99.39%

The promoter and promoter group voted unanimously in favour.

Institutional shareholders also demonstrated strong support, with approximately 98.09% of institutional votes backing the resolution.

Public non-institutional shareholders recorded approval of approximately 99.99%.

The voting pattern indicates broad shareholder acceptance of the company's proposed debt issuance flexibility.

However, shareholder approval should not be interpreted as an assessment of the financial attractiveness of any future NCD tranche.

The terms of individual debt issues will depend on market conditions and the relevant offering documents.

₹2,500 Crore Authorisation Provides One-Year Fundraising Flexibility

The special resolution allows Jubilant Pharmova to issue non-convertible debt securities through private placement during the one-year period following approval.

The aggregate amount outstanding under the authorisation must not exceed ₹2,500 crore at any point.

This distinction is important.

The resolution does not require Jubilant Pharmova to raise the full ₹2,500 crore.

Instead, it gives the company authority to undertake eligible debt transactions within the approved limit.

The company may issue securities in one or more tranches, depending on financing requirements and market conditions.

The timing, pricing and structure of future issues will require separate decisions.

The company must also comply with applicable securities regulations and other legal requirements.

Jubilant Pharmova Already Allotted ₹800 Crore of NCDs

Before the latest shareholder vote, Jubilant Pharmova had completed a separate NCD allotment.

On November 5, 2026, the company's Finance Committee approved the allotment of 80,000 unsecured, rated, listed and redeemable NCDs.

Each debenture had a face value of ₹1 lakh.

The total issue amounted to ₹800 crore.

The securities were allotted at par to successful bidders through private placement.

They carry an annual coupon rate of 8.50% and have a tenure of three years.

The NCDs are listed on BSE.

Completed NCD allotment

₹800 Cr

Shareholder-approved limit

₹2,500 Cr

The ₹800 crore allotment is a completed financing transaction. The ₹2,500 crore figure represents an authorisation ceiling, not an additional completed borrowing.

The earlier transaction provides an example of how the company is accessing debt capital markets.

The latest approval establishes a broader framework for further financing activity.

Annual Interest on ₹800 Crore NCD Issue Estimated at ₹68 Crore

The completed ₹800 crore NCD issue carries an annual coupon of 8.50%.

Based on the stated principal amount and coupon rate, the annual contractual interest amount is approximately ₹68 crore.

Calculation

Amount

NCD principal

₹800 crore

Annual coupon

8.50%

Illustrative annual interest

₹68 crore

Tenure

Three years

Illustrative interest over three years

₹204 crore

The three-year figure assumes the full principal remains outstanding throughout the tenure and excludes any effects of transaction costs, early redemption or other contractual provisions.

Actual interest payment dates and cash flow arrangements are governed by the issue terms.

The coupon represents a financing cost that the company must service according to its obligations.

The financial impact will depend on how the funds are deployed and the returns generated by the underlying business.

What Are Non-Convertible Debentures?

Non-convertible debentures are debt instruments issued by companies to raise funds from investors.

Unlike convertible debentures, NCDs do not provide an automatic right to convert the debt into equity shares.

Investors typically receive interest according to the instrument's terms and repayment of principal at maturity or through an agreed redemption structure.

NCDs may be secured or unsecured.

Secured debentures are backed by specified assets or security arrangements.

Unsecured debentures do not have the same asset-backed security structure.

The risk and pricing of an NCD depend on the issuer's creditworthiness, financial position, maturity, security arrangements and market conditions.

Jubilant Pharmova's November 5 allotment consisted of unsecured NCDs.

Private Placement Allows Targeted Debt Fundraising

A private placement involves issuing securities to a selected group of eligible investors rather than offering them to the general public through a public issue.

Companies frequently use private placements to raise funds from institutional investors and other eligible participants.

The process can provide flexibility in determining the size, maturity and pricing of debt securities.

For established companies, private placements can complement bank borrowing and other financing arrangements.

The pricing of individual issues depends on prevailing interest rates, investor demand and the issuer's credit profile.

Jubilant Pharmova's shareholder approval enables it to use this financing route within the authorised limits.

However, the company has not announced the terms of any additional NCD issuance following the November 20 vote.

Why Jubilant Pharmova Is Expanding Its Debt Fundraising Options

Jubilant Pharmova operates capital-intensive pharmaceutical businesses.

Its operations include radiopharmaceuticals, radiopharmacies, contract development and manufacturing services, and other pharmaceutical activities.

These businesses require investment in manufacturing facilities, technology, regulatory compliance and distribution infrastructure.

Debt financing can provide resources for capital expenditure and other corporate requirements.

It may also allow a company to manage its borrowing maturity profile or refinance existing obligations.

The latest shareholder approval gives Jubilant Pharmova flexibility to access debt capital markets as financing needs arise.

However, the company has not disclosed a specific allocation of the full ₹2,500 crore authorisation across individual projects or financing purposes.

The final use of proceeds will depend on the terms of subsequent issuances.

Pharmaceutical Expansion Requires Significant Capital Investment

Jubilant Pharmova has been investing in its pharmaceutical manufacturing and radiopharmaceutical businesses.

Its expansion programme includes projects in North America.

These include manufacturing capacity additions at Spokane in the United States and Montreal in Canada.

The company has also been expanding its PET radiopharmacy network.

Such investments can support future production capacity and customer demand.

However, they require substantial capital expenditure before the associated facilities generate their full expected revenue.

Manufacturing expansion can also involve regulatory approvals, equipment qualification and operational ramp-up periods.

These factors influence the timing of cash flows and the company's financing requirements.

The debt issuance authorisation could provide financial flexibility during this investment cycle, although specific funding allocations have not been announced.

FY26 Capital Expenditure Exceeded Operating Cash Generation

Jubilant Pharmova reported consolidated capital expenditure of approximately ₹1,449.1 crore during FY26, including investment in property, plant, equipment and intangible assets.

Operating cash generation during the financial year was approximately ₹1,226.8 crore.

The difference illustrates the scale of the company's investment requirements.

The company also reported consolidated borrowings of approximately ₹3,219.5 crore as of March 31, 2026.

These figures provide context for its decision to access debt capital markets.

However, the borrowing position may have changed since the financial year-end.

The November 5 NCD allotment and other financing activities must be considered when assessing the company's current debt position.

Radiopharma and CDMO Businesses Remain Central to Growth Strategy

Jubilant Pharmova's radiopharmaceutical business supplies products used in diagnostic imaging and therapeutic applications.

The business operates in a specialised pharmaceutical segment involving radioactive materials and stringent regulatory requirements.

Its radiopharmacy operations support the distribution and preparation of relevant products for healthcare customers.

The company's contract development and manufacturing organisation, or CDMO, business provides manufacturing services to pharmaceutical clients.

CDMO operations can require substantial investment in specialised production facilities and quality systems.

The company's ongoing projects are intended to support future business growth and manufacturing capacity.

However, the timing of returns depends on successful commissioning, regulatory compliance and commercial demand.

Debt Financing Can Support Growth but Increases Financial Obligations

Debt securities provide capital without immediately issuing additional equity shares.

This can help companies finance expansion while avoiding direct equity dilution.

However, borrowing introduces interest payments and principal repayment obligations.

For Jubilant Pharmova, the ₹800 crore NCD issue creates an annual coupon obligation of approximately ₹68 crore, based on the disclosed rate.

Additional debt issuance could increase financing costs depending on the terms of future transactions.

The company must balance capital investment requirements with cash generation and debt servicing capacity.

Financial flexibility depends not only on access to funding but also on the ability to manage borrowing costs and repayment schedules.

Difference Between Shareholder Approval and Actual Fundraising

The latest announcement concerns shareholder approval for a debt issuance framework.

It does not represent the allotment of ₹2,500 crore of additional securities.

The distinction is particularly relevant because the company has already completed a separate ₹800 crore NCD allotment.

Stage

Status

Board approves ₹800 crore NCD proposal

Completed October 12, 2026

Postal ballot notice issued

Completed October 21, 2026

₹800 crore NCDs allotted

Completed November 5, 2026

Shareholders approve wider NCD authorisation

Completed November 20, 2026

Additional NCD issuance under wider authorisation

Not announced

Final terms of future NCD tranches

Not disclosed

The company can decide whether and when to undertake additional issuances within the applicable authorisation and regulatory framework.

What the Approval Means for Shareholders

The approval provides Jubilant Pharmova with greater flexibility to structure its financing.

It may reduce the need to seek a separate shareholder mandate for each eligible issuance within the approved framework.

For equity shareholders, debt financing avoids immediate dilution from the issuance of new equity shares.

However, debt financing can affect profitability through interest expenses.

The financial impact depends on the amount borrowed, coupon rates, maturity schedules and use of proceeds.

The strong voting support indicates that participating shareholders broadly accepted the proposed financing flexibility.

It does not guarantee that future borrowing will improve earnings or shareholder returns.

What Investors Should Monitor Next

The next important developments will involve any additional NCD issuance announcements.

Investors and market participants will monitor the size, interest rate, tenure and security structure of future tranches.

The company's debt maturity profile and borrowing costs will also be relevant.

Financial results will provide information about operating cash generation and the company's ability to fund capital expenditure.

Progress on manufacturing expansion projects in Spokane, Montreal and the radiopharmacy network will remain important.

Any additional debt issuance will need to be evaluated alongside the company's financial position and expected business performance.

Conclusion

Jubilant Pharmova's shareholders have approved the private placement of non-convertible debt securities, providing the pharmaceutical company with broader borrowing flexibility.

The special resolution was passed on November 20, 2026, with approximately 99.39% of the votes cast in favour.

The approval permits eligible private-placement debt issuances subject to an aggregate outstanding limit of ₹2,500 crore during the one-year authorisation period.

The development follows the company's completed ₹800 crore NCD allotment on November 5, carrying an annual coupon of 8.50% and a three-year tenure.

The fundraising framework comes as Jubilant Pharmova continues investing in radiopharmaceuticals, CDMO manufacturing and related pharmaceutical infrastructure.

However, the ₹2,500 crore approval should not be interpreted as an additional completed fundraising transaction.

The eventual financial implications will depend on future issuances, borrowing costs and the company's ability to generate returns from its investment programme.